Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing factor U2AF 65 kDa subunit (U2AF2) is a key RNA-binding protein essential for pre-mRNA splicing in eukaryotes[1][2]. U2AF2 forms a heterodimer with U2AF1 and is required for the recognition of the polypyrimidine (Py) tract at the 3′ splice site of introns during spliceosome assembly[1][2]. The protein contains three RNA recognition motifs (RRMs) and an arginine/serine-rich (RS) domain, binding to uridine-rich sequences and establishing protein–protein interactions with other splicing factors such as SF1 and UAP56[1]. U2AF2’s activity is critical for spliceosome fidelity—it proofreads and selects strong Py-tracts while disfavoring weak, non-bona fide splice sites; dysregulation of its assembly or RNA binding results in alternative splicing errors[2][3]. Mutations in U2AF2 have been implicated in various cancers, developmental syndromes, retinal disease, cystic fibrosis, and autoimmune conditions[2]. While U2AF2 is not a conventional drug target or receptor, understanding its function is vital for research into RNA biology and the molecular basis of pre-mRNA splicing diseases[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor U2AF 65 kDa subunit (U2AF2).